CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway

MiR-509-3-5p causes aberrant mitosis and anti-proliferative effect by suppression of PLK1 in human lung cancer A549 cells

(2016) Xian-Hui Wang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

The multidrug transporter ABCG2: still more questions than answers

(2016) A. J. Horsey et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer

(2016) Kyong Joo Lee et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies

(2016) Madeleine Duvic et al.   CANCER TREATMENT REVIEWS

Overexpression of miR-509 Increases Apoptosis and Inhibits Invasion via Suppression of Tumor Necrosis Factor-α in Triple-Negative Breast Cancer Hs578T Cells

(2016) Guoqiang Zhang et al.   ONCOLOGY RESEARCH

MicroRNA-509–3p increases the sensitivity of epithelial ovarian cancer cells to cisplatin-induced apoptosis

(2016) Wei Chen et al.   PHARMACOGENOMICS

miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer

(2016) Yinghong Pan et al.   Oncotarget

Synergistic anticancer effects of cisplatin and histone deacetylase inhibitors (SAHA and TSA) on cholangiocarcinoma cell lines

(2015) MD. ALI ASGAR et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies

(2015) Kyu-pyo Kim et al.   INVESTIGATIONAL NEW DRUGS

The microRNA miR-22 inhibits the histone deacetylase HDAC4 to promote TH17 cell–dependent emphysema

(2015) Wen Lu et al.   NATURE IMMUNOLOGY

Effects of the Hippo Signaling Pathway in Human Gastric Cancer

(2014) Guang-Xi Zhou et al.   Asian Pacific Journal of Cancer Prevention

Transforming growth factor-β1-induced epithelial–mesenchymal transition generates ALDH-positive cells with stem cell properties in cholangiocarcinoma

(2014) Ze-Yu Shuang et al.   CANCER LETTERS

Class IIa HDACs - new insights into their functions in physiology and pathology

(2014) Maribel Parra   FEBS Journal

ATP-Binding Cassette Genes Genotype and Expression: A Potential Association with Pancreatic Cancer Development and Chemoresistance?

(2014) Li Pang et al.   Gastroenterology Research and Practice

Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients

(2013) Ju Han et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Gemcitabine plus Cisplatin versus Capecitabine plus Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Retrospective Cohort Study

(2013) Sang Myung Woo et al.   CHEMOTHERAPY

Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial

(2013) William Greenhalf et al.   JNCI-Journal of the National Cancer Institute

Class IIa HDACs repressive activities on MEF2-depedent transcription are associated with poor prognosis of ER+ breast tumors

(2012) Andrea Clocchiatti et al.   FASEB JOURNAL

Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update

(2012) Shahid A Khan et al.   GUT

The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice

(2012) Takuya Kitamura et al.   JOURNAL OF HEPATOLOGY

MicroRNA miR-491-5p Targeting both TP53 and Bcl-XL Induces Cell Apoptosis in SW1990 Pancreatic Cancer Cells through Mitochondria Mediated Pathway

(2012) Rong Guo et al.   MOLECULES

SAHA Inhibits the Growth of Colon Tumors by Decreasing Histone Deacetylase and the Expression of Cyclin D1 and Survivin

(2012) Jong-Shiaw Jin et al.   PATHOLOGY & ONCOLOGY RESEARCH

Phase I–II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo

(2011) B. Ramaswamy et al.   BREAST CANCER RESEARCH AND TREATMENT

Class IIa HDACs: from important roles in differentiation to possible implications in tumourigenesis

(2011) Andrea Clocchiatti et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma

(2011) Prakash Chinnaiyan et al.   NEURO-ONCOLOGY

Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma

(2010) Yuan-Ling Liu et al.   Autophagy

ALDHhigh adenoid cystic carcinoma cells display cancer stem cell properties and are responsible for mediating metastasis

(2010) Shuyang Sun et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity

(2010) J Zhang et al.   BRITISH JOURNAL OF CANCER

Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan

(2010) T Okusaka et al.   BRITISH JOURNAL OF CANCER

Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells

(2010) Eun-Taex Oh et al.   INVESTIGATIONAL NEW DRUGS

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE

MicroRNAs: Target Recognition and Regulatory Functions

(2009) David P. Bartel   CELL

CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells

(2009) Sung Pil Hong et al.   INTERNATIONAL JOURNAL OF CANCER

Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines

(2008) Li-Ning Xu et al.   WORLD JOURNAL OF GASTROENTEROLOGY